Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients
Status:
Completed
Trial end date:
2016-10-24
Target enrollment:
Participant gender:
Summary
The investigators are imaging patients with prostate cancer using a new PET imaging agent
(Ga-68 HBED-CC PSMA) in order to evaluate it's ability to detection prostate cancer in
patients with high risk disease prior to prostatectomy, patients with biochemical recurrence
and patients with castrate resistant prostate cancer.